구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Brentuximab Vedotin (Bv) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Hodgkin Lymphoma |
Overview Indication | Hodgkin Lymphoma (Category) |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Technology Payload | Vedotin: A Retrospective Cohort Study from a Te |
MoA Mechanism | Targeting of the Bradykinin B2 Receptor |
MoA Biomarker | biomarkers; however, these methods do not detect all HPV strains and are not applicable to HPV-negative tumor |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | Intranasal Tat-modified PEG-PCL nanomicelles delivering anti-RelA siRNA attenuate ischemia-reperfusion injury.. Inflammatory responses centered on microglial activation are deeply involved in the progression of cerebral ischemia-reperfusion injury, and RelA, a subunit of nuclear factor κB (NF-κB), acts as a central mediator of these responses. In this study, we evaluated the efficacy o… |
Clinical Safety signal | Intranasal Tat-modified PEG-PCL nanomicelles delivering anti-RelA siRNA attenuate ischemia-reperfusion injury.. Inflammatory responses centered on microglial activation are deeply involved in the progression of cerebral ischemia-reperfusion injury, and RelA, a subunit of nuclear factor κB (NF-κB), acts as a central mediator of these responses. In this study, we evaluated the efficacy o… |
Clinical Selected reported efficacy | ORR 96.4% |
Clinical Reported ORR | 100.0% |
Clinical Reported PFS | 95.2 |
Clinical Result source | ClinicalTrials.gov NCT02927769 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02927769 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Brentuximab Vedotin (Bv) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Hodgkin Lymphoma |
Overview Indication | Hodgkin Lymphoma (Category) |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Technology Payload | Vedotin: A Retrospective Cohort Study from a Te |
MoA Mechanism | Targeting of the Bradykinin B2 Receptor |
MoA Biomarker | biomarkers; however, these methods do not detect all HPV strains and are not applicable to HPV-negative tumor |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | Intranasal Tat-modified PEG-PCL nanomicelles delivering anti-RelA siRNA attenuate ischemia-reperfusion injury.. Inflammatory responses centered on microglial activation are deeply involved in the progression of cerebral ischemia-reperfusion injury, and RelA, a subunit of nuclear factor κB (NF-κB), acts as a central mediator of these responses. In this study, we evaluated the efficacy o… |
Clinical Safety signal | Intranasal Tat-modified PEG-PCL nanomicelles delivering anti-RelA siRNA attenuate ischemia-reperfusion injury.. Inflammatory responses centered on microglial activation are deeply involved in the progression of cerebral ischemia-reperfusion injury, and RelA, a subunit of nuclear factor κB (NF-κB), acts as a central mediator of these responses. In this study, we evaluated the efficacy o… |
Clinical Selected reported efficacy | ORR 96.4% |
Clinical Reported ORR | 100.0% |
Clinical Reported PFS | 95.2 |
Clinical Result source | ClinicalTrials.gov NCT02927769 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02927769 |
추천 비교
추천 비교